

digital PCR

Maido Remm

BIOINFO Journal Club

04.10.2013


Absolute quantification by droplet digital PCR versus analog real-time PCR

Christopher M Hindson^{1,6,7}, John R Chevillet^{2,7},
Hilary A Briggs², Emily N Gallichotte², Ingrid K Ruf²,
Benjamin J Hindson^{1,6}, Robert L Vessella³ &
Muneesh Tewari^{2,4,5}

¹Digital Biology Center, Bio-Rad Laboratories, Inc., Pleasanton, California, USA. ²Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. ³Department of Urology, University of Washington, Seattle, Washington, USA. ⁴Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. ⁵Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. ⁶Present address: 10X Technologies, Pleasanton, California, USA. ⁷These authors contributed equally to this work. Correspondence should be addressed to M.T. (mtewari@fhcrc.org).


RECEIVED 10 APRIL; ACCEPTED 16 JULY; PUBLISHED ONLINE 1 SEPTEMBER 2013; DOI:10.1038/NMETH.2633

real-time PCR (qPCR) = analog PCR






real-time PCR (qPCR)

increase in fluorescence is dependent on amount of template DNA



real-time PCR (qPCR)

estimates quantity of DNA through comparison with calibration curves




digital PCR

Proc. Natl. Acad. Sci. USA
Vol. 96, pp. 9236–9241, August 1999
Genetics


Digital PCR

BERT VOGELSTEIN* AND KENNETH W. KINZLER

The Howard Hughes Medical Institute and the Johns Hopkins Oncology Center, Baltimore, MD 21231



droplet digital PCR



2 main droplet dPCR technologies

BIO-RAD

QX200™ droplet-digital™
PCR system (ddPCR™)



 **RainDance™**
Technologies

RainDrop™ Digital PCR System



2 main droplet dPCR technologies

Table 1 | Commercial digital PCR offerings

Vendor	Instruments and list price	Consumables and list price	Number and volume of partitions	Volumes required	qPCR capacity	Multiplexing
Bio-Rad Laboratories	QX100 ddPCR System (machines to generate and read droplets): \$89,000	8 samples per chip (14,000–16,000 droplets per sample): \$3 per sample	Up to 96 samples per run (assumes manual pipetting into PCR plate); 1,344,000 partitions per run (assuming separate thermocycler runs 12 chips at once) 1 nl per partition	Up to 9 µl per sample (20,000 droplets made); an average of 70% read	No	Uses 2 colors to detect 2 targets
RainDance ^c	RainDrop Digital PCR (machines to generate, collect and read droplets): \$100,000	8 samples per chip (up to 10,000,000 droplets per sample): \$10–\$30 per sample	8 samples per run; up to 80,000,000 partitions per run 5 pl per partition	5–50 µl per sample	No	Uses 2 colors, but can use varying concentrations of probes to detect up to 10 targets


Digital PCR hits its stride

Monya Baker

Nature Methods **9**, 541–544 (2012)

Testing sensitivity and precision

Entire workflow repeated 3 times



Sensitivity

water

plasma

Supplementary Table 4			Supplementary Table 5		
Limit of Quantification (copies per μ L PCR)			Limit of Quantification (copies/ μ L PCR)		
miRNA	ddPCR	Real time PCR	miRNA	ddPCR	Real time PCR
miR-141	0.5	0.5	miR-141	0.25	1
miR-375	0.25	0.5	miR-375	2	8
miR-210	1	1	miR-210	0.5	8
miR-135b	1	8	miR-135b	1	2
miR-205	0.5	0.5	miR-205	1	1
miR-16	0.25	4	miR-16	NA*	NA*

Supplementary Table 4 | Operating characteristics based on ddPCR and real time PCR analysis of synthetic miRNA oligonucleotides (water matrix). Limit of quantification (LOQ) was defined as the lowest concentration tested that remained above or equal to the limit of detection (LOD)* and above or equal to the lower limit of linear range of the assay (LLLR)**. * LOD was defined as $\langle x \rangle_{bi} + ks_{bi}$, where $\langle x \rangle_{bi}$ = mean of the no- template controls, s_{bi} = standard deviation of no-template controls, $k = 2.479$ (99% confidence interval). LOD determinations here are likely to be biased in favor of real time PCR, as undetermined Cts are set uniformly to 40, artificially lowering s_{bi} estimates for real time PCR. ** LLLR was determined by runs-testing, removing successive lowest dilution points until the P -value was >0.05 , indicating no significant deviation from linearity.

Precision





Figure 1 | Quantification of synthetic miRNA oligonucleotides by ddPCR and real-time PCR. (a) Comparative analysis of dilution series of indicated miRNAs in water. Each color represents one preparative (independent preparation of a dilution series) replicate and each shape represents individual RT reactions (RT 1, circle; RT 2, square; and RT 3, triangle). Box and whisker plots (gray) show median (center line), 25th and 75th percentiles (box), and 10th and 90th percentiles (whiskers). NTC, no-template control.

Test with real prostate cancer samples

We focused on the quantification of cDNAs corresponding to microRNAs (miRNAs), which are small regulatory RNA molecules with diverse cellular functions⁷. miRNAs also exist in highly stable extracellular forms in the vascular circulation^{8,9} with potential hormonal function¹⁰ and can be useful as blood-based biomarkers for cancer⁸ and other diseases¹¹.



Day-to-day reproducibility


Supplementary Table 9 | Day-to-day variability of miR-141 quantification from clinical samples (ddPCR vs. standard real time PCR). Results are presented as copies of miR-141 per μL in PCR reaction.

s.d.: standard deviation. %CV: Coefficient of variation calculated from replicates over 3 days (percentage). **Fold-change of %CV was calculated as the ratio of %CV for real time PCR results to %CV for ddPCR results.**

Supplementary Table 9			ddPCR (copies per μL in PCR)						Standard real-time PCR (copies per μL in PCR)						CV Fold Difference
Sample Number	ID	Status	Day 1	Day 2	Day 3	Mean	SD	%CV	Day 1	Day 2	Day 3	Mean	SD	%CV	
1	A	Control	2.20	2.21	3.03	2.48	0.48	19	7.78	2.14	0.39	3.44	3.86	112	6
2	B	Case	3.59	2.40	2.89	2.96	0.60	20	1.54	5.62	0.76	2.64	2.61	99	5
3	C	Control	6.70	4.32	5.47	5.50	1.19	22	7.01	3.77	0.52	3.76	3.25	86	4
4	D	Case	2.52	1.63	2.41	2.19	0.49	22	4.21	3.19	0.50	2.63	1.92	73	3
5	E	Control	4.01	3.09	3.60	3.57	0.46	13	8.91	1.49	0.77	3.72	4.50	121	9
6	F	Case	2.95	2.06	3.01	2.67	0.53	20	3.48	2.02	2.25	2.58	0.78	30	2
7	G	Control	2.70	1.85	2.21	2.26	0.43	19	6.66	2.50	1.81	3.66	2.63	72	4
8	H	Case	6.94	6.23	7.08	6.75	0.46	7	21.76	9.17	13.19	14.71	6.43	44	6
9	I	Control	3.99	3.47	3.91	3.79	0.28	7	9.87	3.23	27.77	13.62	12.70	93	13
10	J	Case	44.45	44.64	46.44	45.18	1.10	2	202.81	46.22	25.77	91.60	96.85	106	43
11	K	Control	2.31	2.38	2.82	2.51	0.28	11	9.62	3.60	46.53	19.92	23.25	117	11
12	L	Case	4.22	3.68	4.49	4.13	0.41	10	0.53	1.18	159.11	53.61	91.37	170	17
13	M	Control	4.04	3.10	2.47	3.20	0.79	25	4.26	2.56	1.03	2.62	1.62	62	3
14	N	Case	8.30	6.88	5.84	7.01	1.23	18	22.36	9.54	2.19	11.36	10.21	90	5
15	O	Control	3.67	3.03	2.35	3.01	0.66	22	3.36	4.23	0.71	2.77	1.84	66	3
16	P	Case	8.70	8.63	7.47	8.27	0.69	8	39.37	12.83	2.95	18.38	18.83	102	12
17	Q	Control	3.59	2.78	2.68	3.02	0.50	16	7.37	4.05	0.50	3.97	3.43	86	5
18	R	Case	21.52	19.05	17.07	19.21	2.23	12	57.76	26.66	8.71	31.04	24.82	80	7

How well miR-141 levels predict cancer?

C



Absolute quantification by droplet digital PCR versus analog real-time PCR

Christopher M Hindson^{1,6,7}, John R Chevillet^{2,7}, Hilary A Briggs², Emily N Gallichotte², Ingrid K Ruf², Benjamin J Hindson^{1,6}, Robert L Vessella³ & Muneesh Tewari^{2,4,5}

¹Digital Biology Center, Bio-Rad Laboratories, Inc., Pleasanton, California, USA. ²Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. ³Department of Urology, University of Washington, Seattle, Washington, USA. ⁴Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. ⁵Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. ⁶Present address: 10X Technologies, Pleasanton, California, USA. ⁷These authors contributed equally to this work. Correspondence should be addressed to M.T. (mtewari@fhcrc.org).

RECEIVED 10 APRIL; ACCEPTED 16 JULY; PUBLISHED ONLINE 1 SEPTEMBER 2013; DOI:10.1038/NMETH.2633

NATURE METHODS | VOL.10 NO.10 | OCTOBER 2013 | 1003

Competing financial interests

C.M.H. and B.J.H. were formerly employees of Quantalife, Inc. and Bio-Rad, Inc., including during periods that the work was done. M.T.'s laboratory received some consumable supplies from Quantalife, Inc. and Bio-Rad, Inc. during the course of the studies. M.T. is an inventor on patent application US 12/993,828 pertaining to extracellular microRNA biomarkers.

Absolute quantification by droplet digital PCR versus analog real-time PCR

Christopher M Hindson^{1,6,7}, John R Chevillet^{2,7},
Hilary A Briggs², Emily N Gallichotte², Ingrid K Ruf²,
Benjamin J Hindson^{1,6}, Robert L Vessella³ &
Muneesh Tewari^{2,4,5}

CONCLUSIONS:

Our comparison of microRNA quantification by ddPCR and real-time PCR revealed **greater precision** (coefficients of variation decreased 37–86%) and **improved day-to-day reproducibility** of ddPCR but with **comparable sensitivity**.

When we applied ddPCR to serum microRNA biomarker analysis, this translated to **superior diagnostic performance** for identifying individuals with cancer.

Differences between droplet PCR and conventional PCR

The relative numbers of reactants are still large; in a 5 picoliter-sized drop, there are approximately 2,500,000 molecules of each primer (900 nM) and 750,000 probe molecules (250 nM).

In ddPCR, **the absolute concentration of a single target molecule, relative to the PCR reagents, is substantially higher** in the nanoliter volume than in conventional microliter-scale PCR. The likelihood of favorable primer-template interactions, and thus, the efficiency, specificity, and sensitivity of ddPCR, is increased in comparison to that of conventional PCR tests.

Similarly, **the fluorescent product is confined to the droplet volume, and so, small changes in fluorescence intensity are more readily detected** by photonics equipment than a similar absolute amount of fluorescence would be by conventional qPCR platforms.

ddPCR is robust against many of the factors that can negatively influence conventional PCR because **the DNA template is sequestered from cross-reacting DNA templates and inhibitory moieties**.

PCR primers and probes?

Plan to amplify a **75–200 bp product**. Short PCR products are typically amplified with higher efficiency than longer ones, but a PCR product should be at least 75 bp long to allow room for placement of the probe.

Design primers that have a GC content of 50–60%.

Strive for a **T_m between 50 and 65°C**.

Calculate T_m values using the nearest-neighbor method, with values of **50 mM for salt concentration and 300 nM for oligonucleotide concentration**.

Adjust primer locations so they are outside the target sequence secondary structure. Avoid repeats of Gs or Cs longer than 3 bases.

Check the forward and reverse primer sequences to ensure that there is no 3' complementarity (to avoid primer-dimer formation).

When designing **probes**, follow these guidelines:

The T_m of each hydrolysis probe should be 5–10°C higher than that of the corresponding primers. In most cases, the probe should have <30 nucleotides between the fluorophore and the quencher to avoid affecting baseline signal intensity. It must not have a G at its 5' end, because this may quench the fluorescence signal even after hydrolysis. Choose a sequence within the target that has a GC content of 30–80% and design the probe to anneal to the strand that has more Gs than Cs (so the probe contains more Cs than Gs). The QX100 system is compatible with FAM dye and either HEX or VIC as a secondary dye.

The QX100 system is not compatible with SYBR[®] Green or EvaGreen double-stranded DNA-binding dyes.

Applications



Development and Evaluation of a Next-Generation Digital PCR Diagnostic Assay for Ocular *Chlamydia trachomatis* Infections

Using ddPCR to measure *C. trachomatis* infectious load in clinical samples (conjunctival swab samples) in presence of inhibitory agents and competing DNA

OPEN ACCESS Freely available online



Quantitative Analysis of Food and Feed Samples with Droplet Digital PCR

Detection of GMO maize strains in concentrations of < 1%


RESEARCH ARTICLE

AMERICAN JOURNAL OF
medical genetics PART
A

A Sensitive and Specific Diagnostic Test for Hearing Loss Using a Microdroplet PCR-Based Approach and Next Generation Sequencing

Amplification of known candidate genes before sequencing. A deafness RDT primer library was then created that consisted of 1,209 amplicons and associated primer pairs.

multiplex dPCR



The method does not need extremely low dilutions

